Fast food diet with CCl4 micro-dose induced hepatic-fibrosis -a novel animal model

BMC Gastroenterology

Volumn 14, Issue 1, 2014, Pages

  Chheda, Tarak K ^a   Shivakumar, Pratibha ^a   Sadasivan, Satish K ^a   Chanderasekharan, Harish ^a   Moolemath, Yogananda ^a   Oommen, Anup M ^a   Madanahalli, Jagannath R ^a   Marikunte, Venkataranganna V ^a  

^a Preclinical Development Connexios Life Sciences Pvt Ltd ^*  (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CARBON TETRACHLORIDE; COLLAGEN; GAMMA GLUTAMYLTRANSFERASE; GLUTATHIONE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRIACYLGLYCEROL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; FAST FOOD; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENE EXPRESSION PROFILING; HISTOLOGY; INFLAMMATION; LIVER FIBROSIS; LIVER INJURY; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; RAT; SEROLOGY; STAGING; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; DISEASE MODEL; LIVER CIRRHOSIS; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; TOXICITY; WISTAR RAT;

ANIMALS; CARBON TETRACHLORIDE; DISEASE MODELS, ANIMAL; FAST FOODS; FEMALE; GENE EXPRESSION PROFILING; INFLAMMATION; LIVER CIRRHOSIS; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE; RATS; RATS, WISTAR;

EID: 84901635795     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-14-89     Document Type: Article

References (48)

1. Kim CH, Younossi ZM. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med 2008, 75(10):721-728. 10.3949/ccjm.75.10.721, 18939388.
2. Sass DA, Chang P, Chopra KB. Nonalcoholic fatty liver disease: a clinical review. Dig Dis Sci 2005, 50(1):171-180. 10.1007/s10620-005-1267-z, 15712657.
3. Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis 2010, 28:155-161. 10.1159/000282080, 20460905.
4. Milić S, Štimac D. Nonalcoholic fatty liver disease/steatohepatitis: epidemiology, pathogenesis. Clinical presentation and treatment. Dig Dis 2012, 30:158-162. 10.1159/000336669, 22722431.
5. Panchal SK, Poudyal H, Arumugam TV, Brown L. Rutin attenuates metabolic changes, nonalcoholic steatohepatitis, and cardiovascular remodeling in high-carbohydrate, high-fat diet-fed rats. J Nutr 2011, 141(6):1062-1069. 10.3945/jn.111.137877, 21508207.
6. Fan CY, Pan J, Chu R, Lee D, Kluckman KD, Usuda N. Hepatocellular and hepatic peroxisomal alterations in mice with a disrupted peroxisomal fatty acyl-coenzyme A oxidase gene. J Biol Chem 1996, 271:24698-24710. 10.1074/jbc.271.40.24698, 8798738.
7. Cook WS, Jain S, Jia Y, Cao WQ, Yeldandi AV, Reddy JK. Peroxisome proliferator-activated receptor alpharesponsive genes induced in the newborn but not prenatal liver of peroxisomal fatty acyl-CoA oxidase null mice. Exp Cell Res 2001, 268:70-76. 10.1006/excr.2001.5266, 11461119.
8. Lu SC, Alvarez L, Huang ZZ, Chen L, An W, Corrales FJ. Methionine adenosyltransferase 1A knockout mice are predisposed to liver injury and exhibit increased expression of genes involved in proliferation. Proc Natl Acad Sci U S A 2001, 98:5560-5565. 10.1073/pnas.091016398, 33252, 11320206.
9. Xu Z, Chen L, Leung L, Yen TS, Lee C, Chan JY. Liver specific inactivation of the Nrf1 gene in adult mouse leads to nonalcoholic steatohepatitis and hepatic neoplasia. Proc Natl Acad Sci U S A 2005, 102:4120-4125. 10.1073/pnas.0500660102, 554825, 15738389.
10. Sato W, Horie Y, Kataoka E, Ohshima S, Dohmen T, Iizuka M. Hepatic gene expression in hepatocyte-specific Pten deficient mice showing steatohepatitis without ethanol challenge. Hepatol Res 2006, 34:256-265. 10.1016/j.hepres.2006.01.003, 16490391.
11. Brix AE, Elgavish A, Nagy TR, Gower BA, Rhead WJ, Wood PA. Evaluation of liver fatty acid oxidation in the leptin-deficient obese mouse. Mol Genet Metab 2002, 75:219-226. 10.1006/mgme.2002.3298, 11914033.
12. Wortham M, He L, Gyamfi M, Copple BL, Wan YJ. The transition from fatty liver to NASH associates with SAMe depletion in db/db mice fed a methionine choline-deficient diet. Dig Dis Sci 2008, 53:2761-2774. 10.1007/s10620-007-0193-7, 3991247, 18299981.
13. Dela Pena A, Leclercq I, Field J, George J, Jones B, Farrell G. NF-kappaB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis. Gastroenterology 2005, 129:1663-1674. 10.1053/j.gastro.2005.09.004, 16285964.
14. Deng QG, She H, Cheng JH, French SW, Koop DR, Xiong S. Steatohepatitis induced by intragastric overfeeding in mice. Hepatology 2005, 42:905-914. 10.1002/hep.20877, 16175602.
15. Zou Y, Li J, Lu C, Wang J, Ge J, Huang Y, Zhang L, Wang Y. High fat emulsion-induced rat model of nonalcoholic steatohepatitis. Life Sci 2006, 79:1100-1107. 10.1016/j.lfs.2006.03.021, 16624332.
16. Fujii T, Fuchs BC, Yamada S, Lauwers GY, Kulu Y, Goodwin JM, Lanuti M, Tanabe KK. Mouse model of carbon tetrachloride induced liver fibrosis: Histopathological changes and expression of CD133 and epidermal growth factor. BMC Gastroenterol 2010, 10:79. 10.1186/1471-230X-10-79, 2912240, 20618941.
17. Hunter AL, Holscher MA, Neal RA. Thioacetamide-induced hepatic necrosis. I. Involvement of the mixed-function oxidase enzyme system. J Pharmacol Exp Ther 1977, 200(2):439-448.
18. Tetri LH, Basaranoglu M, Brunt EM, Yerian LM, Neuschwander-Tetri BA. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol 2008, 295(5):G987-95. 10.1152/ajpgi.90272.2008, 18772365.
19. Starkel P, Leclercq IA. Animal models for the study of hepatic fibrosis. Best Pract Res Clin Gastroenterol 2011, 25(2):319-333. 10.1016/j.bpg.2011.02.004, 21497748.
20. Charlton M, Krishnan A, Viker K, Sanderson S, Cazanave S, McConico A, Masuoko H, Gores G. Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol 2011, 301(5):G825-G834. 10.1152/ajpgi.00145.2011, 3220319, 21836057.
21. Akerboom TP, Sies H. Assay of glutathione, glutathione disulfide, and glutathione mixed disulfides in biological samples. Methods Enzymol 1981, 77:373-382.
22. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979, 95:351-358. 10.1016/0003-2697(79)90738-3, 36810.
23. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-1321. 10.1002/hep.20701, 15915461.
24. Kawasaki T, Igarashi K, Koeda T, Sugimoto K, Nakagawa K, Hayashi S, Yamaji R, Inui H, Fukusato T, Yamanouchi T. Rats fed fructose-enriched diets have characteristics of nonalcoholic hepatic steatosis. J Nutr 2009, 139(11):2067-71. 10.3945/jn.109.105858, 19776184.
25. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006, 43(2 Suppl 1):S99-S112.
26. Paschos P, Paletas K. Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia 2009, 13(1):9-19. 2633261, 19240815.
27. Ramachandran P, Pellicoro A, Vernon MA, Boulter L, Aucott RL, Ali A, Hartland SN, Snowdon VK, Cappon A, Gordon-Walker TT, Williams MJ, Dunbar DR, Manning JR, Van Rooijen N, Fallowfield JA, Forbes SJ, Iredale JP. Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis. Proc Natl Acad Sci U S A 2012, 109(46):E3186-E3195. 10.1073/pnas.1119964109, 3503234, 23100531.
28. Tsukamoto H, Matsuoka M, French SW. Experimental models of hepatic fibrosis: a review. Semin Liver Dis 1990, 10:56-65. 10.1055/s-2008-1040457, 2110685.
29. Constandinou C, Henderson N, Iredale JP. Modeling liver fibrosis in rodents. Methods Mol Med 2005, 117:237-250.
30. Radice S, Marabini L, Gervasoni M, Ferraris M, Chiesara E. Adaptation to oxidative stress: effects of vinclozolin and iprodione on the HepG2 cell line. Toxicology 1998, 129:183-191. 10.1016/S0300-483X(98)00086-9, 9772096.
31. Shi J, Aisaki K, Ikawa Y, Wake K. Evidence of hepatocyte apoptosis in rat liver after the administration of carbon tetrachloride. Am J Pathol 1998, 153(2):515-525. 10.1016/S0002-9440(10)65594-0, 1852991, 9708811.
32. Abdelmalek MF, Suzuki A, Guy C, Unalp-Arida A, Colvin R, Johnson RJ, Diehl AM. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 2010, 51:1961-1971. 10.1002/hep.23535, 2922495, 20301112.
33. Ouyang X, Cirillo P, Sautin Y, McCall S, Bruchette JL, Diehl AM, Johnson RJ, Abdelmalek MF. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol 2008, 48:993-999. 10.1016/j.jhep.2008.02.011, 2423467, 18395287.
34. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011, 140:124-131. 10.1053/j.gastro.2010.09.038, 20858492.
35. Han D, Hanawa N, Saberi B, Kaplowitz N. Mechanisms of liver injury. III Role of glutathione redox status in liver injury. Am J Physiol Gastrointest Liver Physiol 2006, 291(1):G1-G7. 10.1152/ajpgi.00001.2006, 16500922.
36. Fraga CG, Leibovitz BE, Tappel AL. Lipid peroxidation measured as thiobarbituric acid-reactive substances in tissue slices: characterization and comparison with homogenates and microsomes. Free Radic Biol Med 1988, 4(3):155-161. 10.1016/0891-5849(88)90023-8, 3356355.
37. Bezerra FJ, Rezende AA, Rodrigues SJ. Almeida Md: Thiobarbituric acid reactive substances as an index of lipid peroxidation in sevoflurane-treated rats. Rev Bras Anestesiol 2004, 54(5):640-649. 10.1590/S0034-70942004000500004, 19471772.
38. Hu Bscher SG. Histological assessment of non-alcoholic fatty liver disease. Histopathology 2006, 49:450-465. 10.1111/j.1365-2559.2006.02416.x, 17064291.
39. Hamdy N, El-Demerdash E. New therapeutic aspect for carvedilol: antifibrotic effects of carvedilol in chronic carbon tetrachloride-induced liver damage. Toxicol Appl Pharmacol 2012, 261(3):292-299. 10.1016/j.taap.2012.04.012, 22543095.
40. Greco D, Kotronen A, Westerbacka J, Puig O, Arkkila P, Kiviluoto T, Laitinen S, Kolak M, Fisher RM, Hamsten A, Auvinen P, Yki-Järvinen H. Gene expression in human NAFLD. Am J Physiol Gastrointest Liver Physiol 2008, 294(5):G1281-G1287. 10.1152/ajpgi.00074.2008, 18388185.
41. Sahai A, Malladi P, Melin-Aldana H, Green RM, Whitington PF. Upregulation of osteopontin expression is involved in the development of nonalcoholic steatohepatitis in a dietary murine model. Am J Physiol Gastrointest Liver Physiol 2004, 287(1):G264-G273. 10.1152/ajpgi.00002.2004, 15044174.
42. Plaa GL. Chlorinated methanes and liver injury: highlights of the past 50 years. Annu Rev Pharmacol Toxicol 2000, 40:42-65.
43. Weber LW, Boll M, Stampfl A. Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model. Crit Rev Toxicol 2003, 33:105-136. 10.1080/713611034, 12708612.
44. Koteish A, Diehl AM. Animal models of steatosis. Semin Liver Dis 2001, 21:89-104. 10.1055/s-2001-12932, 11296700.
45. Bradbury MW, Berk PD. Lipid metabolism in hepatic steatosis. Clin Liver Dis 2004, 8:639-671. 10.1016/j.cld.2004.04.005, 15331068.
46. Anstee QM, Goldin RD. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol 2006, 87:1-16. 10.1111/j.0959-9673.2006.00465.x, 2517349, 16436109.
47. Day CP, Saksena S. Non-alcoholic steatohepatitis: definitions and pathogenesis. J Gastroenterol Hepatol 2002, 17(Suppl 3):S377-S384.
48. Marra F, Gastaldelli A, Svegliati Baroni G, Tell G, Tiribelli C. Molecular basis and mechanisms of progression of nonalcoholic steatohepatitis. Trends Mol Med 2008, 14:72-81. 10.1016/j.molmed.2007.12.003, 18218340.